{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:01:54Z","timestamp":1792677714167,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cca.2024.120085","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T17:00:47Z","timestamp":1733850047000},"page":"120085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A model based on chitinase 3-like protein for expecting liver severity of hepatitis B virus infections in the immune tolerance phase"],"prefix":"10.1016","volume":"567","author":[{"given":"Jia-Lan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Wu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Han","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cca.2024.120085_b0005","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The global burden of liver disease","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.cca.2024.120085_b0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.cca.2024.120085_b0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2024.120085_b0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cca.2024.120085_b0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2024.120085_b0030","unstructured":"Organization, W. H., Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection 2024."},{"issue":"6","key":"10.1016\/j.cca.2024.120085_b0035","first-page":"401","article-title":"Chinese Medical Association, Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Chinese Journal of","volume":"15","author":"Chinese Society of Hepatology","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cca.2024.120085_b0040","doi-asserted-by":"crossref","unstructured":"Liver., E. A. f. t. S. o. t., EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017, 67 (2), 370-398.doi:10.1016\/j.jhep.2017.03.021.","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"8","key":"10.1016\/j.cca.2024.120085_b0045","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.cca.2024.120085_b0050","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1053\/j.gastro.2017.03.016","article-title":"American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases","volume":"152","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cca.2024.120085_b0055","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/jvh.13606","article-title":"Baseline HBV-DNA load plus AST\/ALT ratio predicts prognosis of HBV-related hepatocellular carcinoma after hepatectomy: A multicentre study","volume":"28","author":"Shen","year":"2021","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.cca.2024.120085_b0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.cca.2024.120085_b0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0168-8278(00)80095-1","article-title":"Serum YKL-40 is increased in patients with hepatic fibrosis","volume":"32","author":"Johansen","year":"2000","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2024.120085_b0070","doi-asserted-by":"crossref","unstructured":"Nishimura, N., et al., Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci U S A 2021, 118 (17).doi:10.1073\/pnas.2019633118.","DOI":"10.1073\/pnas.2019633118"},{"key":"10.1016\/j.cca.2024.120085_b0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-physiol-012110-142250","article-title":"Role of chitin and chitinase\/chitinase-like proteins in inflammation, tissue remodeling, and injury","volume":"73","author":"Lee","year":"2011","journal-title":"Annu. Rev. Physiol."},{"issue":"11","key":"10.1016\/j.cca.2024.120085_b0080","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/hepr.13396","article-title":"Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis","volume":"49","author":"Higashiyama","year":"2019","journal-title":"Hepatol. Res."},{"issue":"5","key":"10.1016\/j.cca.2024.120085_b0085","first-page":"337","article-title":"Diagnostic value of serum chitinase-3-like protein 1 in chronic liver disease of significant fibrosis and cirrhosis","volume":"26","author":"Li","year":"2018","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"1","key":"10.1016\/j.cca.2024.120085_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hep. Intl."},{"issue":"4","key":"10.1016\/j.cca.2024.120085_b0095","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cca.2024.120085_b0100","first-page":"131","article-title":"Expert opinion on expanding anti-HBV treatment for chronic hepatitis B","volume":"30","author":"Chinese Society of Hepatology","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"6","key":"10.1016\/j.cca.2024.120085_b0105","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"EASL Clinical Practice Guidelines on hepatitis E virus infection","volume":"68","author":"Liver","year":"2018","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.cca.2024.120085_b0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","author":"Liver","year":"2023","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.cca.2024.120085_b0115","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series(\u2606)","volume":"73","author":"Liver","year":"2020","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.cca.2024.120085_b0120","first-page":"1050","article-title":"Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)","volume":"60","author":"Chinese Society of Hepatology","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"11","key":"10.1016\/j.cca.2024.120085_b0125","first-page":"846","article-title":"Chinese guidelines on the management of liver cirrhosis","volume":"27","author":"Chinese Society of Hepatology","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"6","key":"10.1016\/j.cca.2024.120085_b0130","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Liver","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2024.120085_b0135","unstructured":"Organization, W. H., WHO Guidelines Approved by the Guidelines Review Committee. In Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, World Health Organization Copyright \u00a9 World Health Organization 2015.: Geneva, 2015."},{"issue":"3","key":"10.1016\/j.cca.2024.120085_b0140","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cca.2024.120085_b0145","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cca.2024.120085_b0150","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2194436","article-title":"Development and validation of a prediction model for the early occurrence of acute kidney injury in patients with acute pancreatitis","volume":"45","author":"Wu","year":"2023","journal-title":"Ren. Fail."},{"issue":"1","key":"10.1016\/j.cca.2024.120085_b0155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jgh.13452","article-title":"A noninvasive model to predict liver histology in HBeAg-positive chronic hepatitis B with alanine aminotransferase \u2264\u20092upper limit of normal","volume":"32","author":"Gao","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cca.2024.120085_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2016.09.007","article-title":"Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels","volume":"52","author":"Ormeci","year":"2016","journal-title":"Int. J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.cca.2024.120085_b0165","first-page":"746","article-title":"Analysis of hepatic pathological inflammation and fibrosis condition and its influencing factors in 721 patients with chronic hepatitis B with normal ALT","volume":"30","author":"Ning","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"10","key":"10.1016\/j.cca.2024.120085_b0170","first-page":"891","article-title":"Clinicopathological analysis in patients with chronic hepatitis B virus infection in immune tolerant phase","volume":"60","author":"Hu","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"04","key":"10.1016\/j.cca.2024.120085_b0175","first-page":"558","article-title":"Analysis on the judgment values of three non-invasive score systems(LIF-5\uff0cAP\uff32I and FIB-4) for treatment indication in chronic HBV infected patients with ALT less than two times of upper limits of norm","volume":"15","author":"Jiang","year":"2017","journal-title":"Chin. J. General Pract."},{"issue":"S1","key":"10.1016\/j.cca.2024.120085_b0180","article-title":"THU412 - Establishment of a new diagnostic model for significant liver tissue damage in patients with chronic hepatitis B virus infection in the immune tolerance phase","volume":"77","author":"Airong","year":"2022","journal-title":"J. Hepatol."},{"issue":"168","key":"10.1016\/j.cca.2024.120085_b0185","first-page":"41","article-title":"Serum CHI3L1 as a biomarker for non-invasive diagnosis of liver fibrosis","volume":"33","author":"Bao","year":"2022","journal-title":"Discov. Med."},{"key":"10.1016\/j.cca.2024.120085_b0190","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.2147\/IJGM.S364602","article-title":"The value of serum CHI3L1 for the diagnosis of chronic liver diseases","volume":"15","author":"Qiu","year":"2022","journal-title":"Int J Gen Med"},{"issue":"6","key":"10.1016\/j.cca.2024.120085_b0195","first-page":"4090","article-title":"Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B","volume":"14","author":"Li","year":"2022","journal-title":"Am. J. Transl. Res."},{"issue":"4","key":"10.1016\/j.cca.2024.120085_b0200","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.hbpd.2020.05.009","article-title":"Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China","volume":"19","author":"Jin","year":"2020","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"5","key":"10.1016\/j.cca.2024.120085_b0205","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.21037\/apm-21-957","article-title":"A noninvasive diagnostic model for significant liver fibrosis in patients with chronic hepatitis B based on CHI3L1 and routine clinical indicators","volume":"10","author":"Huang","year":"2021","journal-title":"Ann. Palliat. Med."},{"issue":"9","key":"10.1016\/j.cca.2024.120085_b0210","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S2468-1253(23)00236-4","article-title":"Is it time for a paradigm shift in treatment guidelines for chronic hepatitis B?","volume":"8","author":"Johannessen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124023386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124023386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T18:41:59Z","timestamp":1737830519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124023386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"alternative-id":["S0009898124023386"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.120085","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model based on chitinase 3-like protein for expecting liver severity of hepatitis B virus infections in the immune tolerance phase","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.120085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120085"}}